Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

The pathophysiology and treatment of depression have been the focus of intense research
and while there is much that remains unknown, modern neurobiological approaches are …

Major depressive disorder (MDD) is one of the most common mental disorders. We
designed a fast-onset antidepressant that works by disrupting the interaction between the …

Clinical and preclinical studies have demonstrated that depression, one of the most common
psychiatric illnesses, is associated with reduced levels of neurotrophic factors, including …

Major depressive disorder (MDD) is a highly prevalent and disabling disorder. Despite the
many hypotheses proposed to understand the molecular pathophysiology of depression, it is …

Neurotrophic factors are a family of growth factors that modulate cellular growth, survival,
and differentiation. For many decades, it has been generally believed that a lack of …

Roxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that
has demonstrated favorable safety and efficacy in the treatment of renal anemia. Recent …

The neurotrophic hypothesis of depression proposes that reduced levels of brain-derived
neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) contribute to …

Background Activity-dependent release of brain-derived neurotrophic factor (BDNF) in the
medial prefrontal cortex (mPFC) is essential for the rapid and sustained antidepressant …

Although currently available antidepressants increase monoamine levels soon after the start
of treatment, therapeutic benefits are often delayed by several weeks and the majority of …